Reported Saturday, Intellia Therapeutics' Lonvo-z Achieves 87% Attack Reduction And 62% Attack-Free Rate In Phase 3 HAELO Trial With Results Published Simultaneously In New England Journal Of Medicine

뉴스 본문을 불러오고 있어요.

Reported Saturday, Intellia Therapeutics' Lonvo-z Achieves 87% Attack Reduction And 62% Attack-Free Rate In Phase 3 HAELO Trial With Results Published Simultaneously In New England Journal Of Medicine | 웨이프 WAPE

Reported Saturday, Intellia Therapeutics' Lonvo-z Achieves 87% Attack Reduction And 62% Attack-Free Rate In Phase 3 HAELO Trial With Results Published Simultaneously In New England Journal Of Medicine

기사 요약

관련 종목

댓글 —